These algorithms are intended for both autonomous and semi-autonomous analysis of vital sign signals, cardiac images, echocardiograms, and can provide a range of measurements and calculations related to physiologic and pathologic cardiac function. These algorithms have been validated in numerous clinical studies and are used in Medicalgorithmics’ own product line as well as licensed to other companies for use in their products.
We have been pioneers in this field, and DRAI is a testament to our expertise in AI development for medical applications. In terms of competitors, there are very few AI algorithms for ECG analysis that have received FDA clearance. This makes DRAI a unique and groundbreaking technology that can help transform the healthcare industry.
Medicalgorithmics has been continuously developing DRAI to remain at the forefront of heart rhythm analysis technology, and we are committed to adhering to the FDA guidelines for AIML-enabled medical devices. As part of our commitment to the healthcare industry, we have contributed a complete set of over 9 million reference beat and rhythm annotations for the PhysioNet Long-Term AF Database.
Research is being conducted on new algorithms for automatic analysis of ECG and CT data.
The company offers and constantly improves software that is used in monitoring centers and hospitals for ECG analysis.
Work is currently underway on a platform for analyzing ECG data and a platform for analyzing CT data.
The company has proprietary PocketECG and QPatch devices. Scheduling is added multi-channel patch and new integrations with third-party devices.